Propranolol

Generic Name: Propranolol

Brand Names: Hemangeol, Hemangiol, Inderal, Innopran

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁NO_₂

CAS Number: 525-66-6

Unique Ingredient Identifier: 9Y8NXQ24VQ

Background: Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.

Propranolol was granted FDA approval on 13 November 1967.

Indication: Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.

Associated Conditions: Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)

Associated Therapies: -

Clinical Trials

Propranolol in Primary Progressive Aphasia

Early Phase 1

Recruiting

Conditions: Aphasia, Primary Progressive

Interventions: Drug: Propranolol
Device: Magnetic Resonance Imaging (MRI)
Drug: Placebo

First Posted Date: 2023-10-04

Last Posted Date: 2024-12-20

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 30

Registration Number: NCT06066710

Locations: 🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States

Naltrexone and Propranolol Combined With Immunotherapy

Phase 1

Recruiting

Conditions: Advanced Melanoma

Interventions: Drug: Propranolol
Drug: Naltrexone

First Posted Date: 2023-08-01

Last Posted Date: 2023-11-15

Lead Sponsor: Ryan Stephenson

Target Recruit Count: 12

Registration Number: NCT05968690

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma Adult
Undifferentiated Pleomorphic Sarcoma
Angiosarcoma

Interventions: Drug: Propranolol
Drug: Pembrolizumab

First Posted Date: 2023-07-27

Last Posted Date: 2023-07-27

Lead Sponsor: Niels Junker

Target Recruit Count: 80

Registration Number: NCT05961761

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway
🇩🇰
Herlev Gentofte Hospital, Herlev, Denmark
🇩🇰
Aarhus University Hospital, Aarhus, Denmark

and more 1 locations

Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery

Phase 4

Recruiting

Conditions: Stress Disorders, Post-Traumatic

Interventions: Behavioral: Memory reactivation procedures
Drug: Propranolol

First Posted Date: 2023-05-11

Last Posted Date: 2024-04-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT05853627

Locations: 🇺🇸
Massachusetts General Hospital Home Base Program, Charlestown, Massachusetts, United States

Lacosamide Versus Propranolol in Migraine

Phase 3

Completed

Conditions: Migraine Disorders

Interventions: Drug: Lacosamide tablet
Drug: Propranolol

First Posted Date: 2023-05-10

Last Posted Date: 2024-05-01

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 600

Registration Number: NCT05851781

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Anabolic Steroid and Propranolol in Paediatric Burn

Not Applicable

Recruiting

Conditions: Bone
Development
Growth
Arrest

Interventions: Drug: Propranolol
Drug: Nandrolone Decanoate

First Posted Date: 2023-04-10

Last Posted Date: 2023-04-10

Lead Sponsor: King Edward Medical University

Target Recruit Count: 114

Registration Number: NCT05805553

Locations: 🇵🇰
King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan

A Study of Propranolol to Treat Kaposi Sarcoma

Phase 2

Not yet recruiting

Conditions: Kaposi Sarcoma

Interventions: Drug: Propranolol

First Posted Date: 2023-04-04

Last Posted Date: 2024-02-28

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 25

Registration Number: NCT05797662

Locations: 🇰🇪
Moi University School of Medicine, Eldoret, Kenya
🇧🇷
Complexo Hospitalar Universitário Professor Edgard Santos, Salvador, Brazil
🇧🇷
Instituto Nacional de Câncer José de Alencar, Rio De Janeiro, Brazil

and more 6 locations